array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2433)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(112) "Our drug pricing system is broken. A Prescription Drug Affordability Board could help fix it. - Virginia Mercury"
["snippet_en"]=>
string(158) "Setting limits on high-cost drugs is the right thing to do, especially in Virginia, whose residents spend more money on our prescriptions than most Americans."
["url"]=>
string(131) "https://virginiamercury.com/2024/02/29/our-drug-pricing-system-is-broken-a-prescription-drug-affordability-board-could-help-fix-it/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/11daa347-d023-457a-bc46-6c3fc444e90d"
["source"]=>
string(19) "virginiamercury.com"
["publication_date"]=>
string(10) "2024-02-29"
["categories"]=>
array(2) {
[0]=>
string(24) "Access and affordability"
[1]=>
string(21) "Shareholders Feedback"
}
}
[1]=>
array(7) {
["title_en"]=>
string(62) "Guest opinion: A New Year’s resolution – Lower drug prices"
["snippet_en"]=>
string(237) "Each January, many Utahns and other Americans resolve to take steps to improve their health over the coming year. Why not also ask Congress to make a resolution that can help us all: voting to reform our prescription drug pricing system?"
["url"]=>
string(129) "https://www.heraldextra.com/news/opinion/local-guest-opinions/2024/jan/30/guest-opinion-a-new-years-resolution-lower-drug-prices/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/2cbefa9b-dcf3-4cfd-9488-2c94e022b000"
["source"]=>
string(15) "heraldextra.com"
["publication_date"]=>
string(10) "2024-01-29"
["categories"]=>
array(2) {
[0]=>
string(24) "Access and affordability"
[1]=>
string(21) "Intellectual Property"
}
}
[2]=>
array(7) {
["title_en"]=>
string(32) "Health Care Roundup: Market Talk"
["snippet_en"]=>
string(134) "Find insight on Helen of Troy, Sanofi, Regeneron Pharmaceuticals and more in the latest Market Talks covering the Health Care sector."
["url"]=>
string(74) "https://www.wsj.com/health/pharma/health-care-roundup-market-talk-9be34cf2"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/677d9872-b550-40fd-8cd7-8862120f1ed8"
["source"]=>
string(7) "wsj.com"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(5) {
[0]=>
string(11) "Competition"
[1]=>
string(16) "Customer Welfare"
[2]=>
string(24) "Access and affordability"
[3]=>
string(15) "Market Movement"
[4]=>
string(24) "Employee Health & Safety"
}
}
[3]=>
array(7) {
["title_en"]=>
string(128) "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries"
["snippet_en"]=>
string(158) "/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international..."
["url"]=>
string(182) "https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a5536b51-142d-4a07-8c9b-f46a94f9b2c2"
["source"]=>
string(16) "prnewswire.co.uk"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(3) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(24) "Access and affordability"
[2]=>
string(13) "Collaboration"
}
}
[4]=>
array(7) {
["title_en"]=>
string(73) "Top 10 Hearing News Stories of 2023 | Hearing Health & Technology Matters"
["snippet_en"]=>
string(96) "In 2023, the landscape of hearing healthcare experienced remarkable activity and pivotal shifts."
["url"]=>
string(79) "https://hearinghealthmatters.org/hearing-news-watch/2023/top-10-audiology-news/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/72fe557d-deae-43f0-abbd-41cb1875b171"
["source"]=>
string(24) "hearinghealthmatters.org"
["publication_date"]=>
string(10) "2023-12-23"
["categories"]=>
array(1) {
[0]=>
string(24) "Access and affordability"
}
}
[5]=>
array(7) {
["title_en"]=>
string(102) "White House keeps focus on lowering drug prices, turns Regeneron's contract language into new standard"
["snippet_en"]=>
string(285) "As President Joe Biden struggles in the most recent 2024 general election polls, the White House is keeping its focus on drug prices, going after pharma for the second time in as many weeks, with plans to find new ways to interact with industry on the federal government's terms. While"
["url"]=>
string(120) "https://endpts.com/white-house-keeps-focus-on-lowering-drug-prices-turns-regenerons-contract-language-into-new-standard/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a8dc7049-0cf9-4523-8a5e-cc5c3d0ba73d"
["source"]=>
string(10) "endpts.com"
["publication_date"]=>
string(10) "2023-12-14"
["categories"]=>
array(6) {
[0]=>
string(20) "Contract negotiation"
[1]=>
string(8) "Politics"
[2]=>
string(24) "Access and affordability"
[3]=>
string(19) "Government Policies"
[4]=>
string(24) "Government Interventions"
[5]=>
string(11) "US Politics"
}
}
[6]=>
array(7) {
["title_en"]=>
string(18) "ADVENT Dermatology"
["snippet_en"]=>
string(119) "ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron..."
["url"]=>
string(79) "https://www.emjreviews.com/dermatology/infographics/advent-dermatology-j030123/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/8ca73ff1-f102-461d-97ee-30543d4febf7"
["source"]=>
string(14) "emjreviews.com"
["publication_date"]=>
string(10) "2023-11-23"
["categories"]=>
array(1) {
[0]=>
string(24) "Access and affordability"
}
}
[7]=>
array(7) {
["title_en"]=>
string(74) "Gianfranco Valenzano becomes Value & Access Director of Astrazeneca Italia"
["snippet_en"]=>
string(265) "Starting from October, Gianfranco Valenzano holds the new role of Value & Access Director of AstraZeneca Italia, the local branch of the global biopharmaceutical company, reporting directly to Francesca Patarnello, Vice President Market Access & Government Affairs."
["url"]=>
string(118) "https://www.pharmastar.it/news/business/gianfranco-valenzano-diventa-value-access-director-di-astrazeneca-italia-42606"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/001b4b5d-bfb4-4f5f-9cf3-1f4f4246cb0c"
["source"]=>
string(13) "pharmastar.it"
["publication_date"]=>
string(10) "2023-10-27"
["categories"]=>
array(4) {
[0]=>
string(12) "Board Change"
[1]=>
string(24) "Access and affordability"
[2]=>
string(10) "Relocation"
[3]=>
string(12) "Staff hiring"
}
}
[8]=>
array(7) {
["title_en"]=>
string(50) "For Riccardo Samele new role in Regeneron in Italy"
["snippet_en"]=>
string(115) "Riccardo Samele joins Regeneron to guarantee Italian patients access to innovative therapies in the oncology field."
["url"]=>
string(102) "https://www.corrierenazionale.it/2023/10/17/per-riccardo-samele-nuovo-incarico-in-regeneron-in-italia/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/681d881d-403a-42cb-b1da-070df9baa089"
["source"]=>
string(20) "corrierenazionale.it"
["publication_date"]=>
string(10) "2023-09-07"
["categories"]=>
array(3) {
[0]=>
string(12) "Staff hiring"
[1]=>
string(24) "Access and affordability"
[2]=>
string(37) "Product Design & Lifecycle Management"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(99)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[22]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2433 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Setting limits on high-cost drugs is the right thing to do, especially in Virginia, whose residents spend more money on our prescriptions than most Americans.
Each January, many Utahns and other Americans resolve to take steps to improve their health over the coming year. Why not also ask Congress to make a resolution that can help us all: voting to reform our prescription drug pricing system?
/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international...
As President Joe Biden struggles in the most recent 2024 general election polls, the White House is keeping its focus on drug prices, going after pharma for the second time in as many weeks, with plans to find new ways to interact with industry on the federal government's terms. While
Starting from October, Gianfranco Valenzano holds the new role of Value & Access Director of AstraZeneca Italia, the local branch of the global biopharmaceutical company, reporting directly to Francesca Patarnello, Vice President Market Access & Government Affairs.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
